US2015252106A1PendingUtilityA1

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

51
Assignee: AVAXIA BIOLOGICS INCPriority: Jul 16, 2007Filed: Mar 16, 2015Published: Sep 10, 2015
Est. expiryJul 16, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Barbara S. Fox
A61P 9/12A61P 9/10A61P 5/48A61P 9/04A61P 3/06A61P 7/10A61P 3/10A61P 3/00A61P 27/02A61P 25/00A61P 29/00A61P 35/00A61P 3/04C07K 16/2896A61P 1/04A61K 2039/505C07K 2317/34C07K 2317/12C07K 16/28A61P 19/06C07K 2317/76C07K 16/04A61P 13/12
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising an antibody specific for an apical intestinal receptor in the gastrointestinal tract of a patient, wherein the apical intestinal receptor is a sugar receptor or transporter, wherein the pharmaceutical composition is formulated for direct delivery to the gastrointestinal (GI) tract of the patient, and wherein the antibody is derived from the milk or colostrum of a ruminant animal.

Join the waitlist — get patent alerts

Track US2015252106A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.